What are Drug-drug Interactions Anyway?
A current buzz phrase in pharmaceutical research right now is “drug-drug interaction” or simply “drug…
CertaraJanuary 5, 2011
The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain
ATP-binding cassette transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) have been shown to…
CertaraJanuary 1, 2011
Absorption Rate
The rate at which a drug enters the body after administration is called the absorption…
CertaraDecember 30, 2010
What is a Half-life?
One of the most incorrectly used but most often quoted parameters is half life. The…
CertaraDecember 20, 2010
Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales
This article demonstrates techniques for describing and predicting disease progression in acute stroke by modeling…
CertaraDecember 1, 2010
Development of a Modeling Framework to Simulate Efficacy Endpoints for Motesanib in Thyroid Cancer Patients
To develop a modeling framework that simulates clinical endpoints (objective response rate and progression-free survival)…
CertaraNovember 1, 2010
Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients
To develop a population pharmacokinetic/pharmacodynamic model describing the relationship between motesanib exposure and tumor response…
CertaraNovember 1, 2010
A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551
Pharmacokinetic-pharmacodynamic relationships are crucial in understanding a drug's arrhythmogenic potential. Models assist to quantitatively relate…
CertaraAugust 21, 2010
Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis
In this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients…
CertaraJuly 1, 2010
